A Novel Elevated Plus-Maze Procedure to Avoid the One-Trial Tolerance Problem
Open Access
- 1 January 2011
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 5, 43
Abstract
The elevated plus-maze (EPM) test is one of the most commonly used behavioral assays to evaluate anxiety-related behavior in rodents. It is an economic test (5 min duration) without prior conditioning of the animals. The critical measure for anxiety is the time spent in the open arms of the maze. A confounding problem of the EPM is the so called one-trial tolerance (OTT), characterized by a marked decrease of open arm exploration in spite of treatment with anxiolytic acting benzodiazepines upon re-exposure to the EPM. This consistent finding is often raised as an evidence for the inappropriateness to re-test rodents in the EPM. However, a reliable re-test paradigm would broaden the usability and effectiveness of this test. Therefore, we tested how an extension of the inter-trial interval to 28 days (instead of the usual 24 h), and an additional change of the testing room would affect the open arm time and other behaviors on the EPM. In two experiments, drug-naive Wistar rats were exposed to the EPM on trial 1, and treated intraperitoneally with either vehicle or midazolam (0.25 mg/kg) 30 min before trial 2. Then, trial 2 (28 days after trial 1) was carried out in either the same testing room (Experiment 1) or in another unfamiliar room (Experiment 2). Twenty-eight days after trial 1 the open arm time of the rats in the vehicle treated control rats of both experimental groups was comparable to that of the first trial, independent of the testing room. Most importantly, we found that the treatment with the benzodiazepine midazolam had a significantly anxiolytic-like (i.e., increase of open arm time) effect in trial 2 only when conducted in the previously unfamiliar testing room (Experiment 2). We suggest that in order to reliably re-test the EPM and to prevent confounding effects due to the OTT, an inter-trial interval of 28 days and a change in testing rooms reinstates anxiolytic-like actions of benzodiazepines.Keywords
This publication has 33 references indexed in Scilit:
- An integrated genome research network for studying the genetics of alcohol addictionAddiction Biology, 2010
- Animal models of human psychopathology based on individual differences in novelty-seeking and anxietyNeuroscience & Biobehavioral Reviews, 2008
- The use of the elevated plus maze as an assay of anxiety-related behavior in rodentsNature Protocols, 2007
- Role of learning of open arm avoidance in the phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in miceLife Sciences, 2005
- Different data from different labs: Lessons from studies of gene–environment interactionJournal of Neurobiology, 2002
- One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic-sensitive behaviors in the elevated plus-maze retest in the ratPharmacology Biochemistry and Behavior, 2002
- The phenomenon of “one-trial tolerance” to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze is abolished by the introduction of a motivational conflict situationLife Sciences, 1999
- Influence of Prior Experience on Mice Behavior Using the Four-Plate TestPharmacology Biochemistry and Behavior, 1997
- Plus-maze retest profile in mice: Importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockadePharmacology Biochemistry and Behavior, 1996
- The interplay of learning and anxiety in the elevated plus-mazeBehavioural Brain Research, 1993